Endocarditis due to Streptococcus pneumoniae is unusual in children, accounting for 3%-7% of all cases of childhood endocarditis. The US Pediatric Multicenter Pneumococcal Surveillance Group has prospectively identified patients with invasive disease at 8 children's hospitals. During the period of 1 September 1993 through 28 February 2003, a total of 11 children with pneumococcal endocarditis were seen. Seven (64%) were 3-36 months old; 8 (73%) were boys. Ten (91%) had preexisting structural heart disease; 5 had undergone previous heart surgery. Concomitant sites of infection were noted in 6 patients (55%), including 3 patients with meningitis. One patient (9%) died during hospitalization, and 5 others (45%) experienced serious complications. Only 2 patients remained hospitalized for their entire course of parenteral antibiotic therapy. Eight of 10 pneumococcal isolates tested were vaccine or vaccine-related serotypes included in the currently licensed 7-valent conjugated pneumococcal vaccine. Pneumococcal endocarditis in children is unusual but often has serious complications.
Although Streptococcus pneumoniae accounts for 3%-7% of cases of endocarditis in children [1] [2] [3] [4] , few series have been reported in the literature. In 1990, Elward et al. [5] reported a case of pneumococcal endocarditis in a child and reviewed the previous 18 pediatric cases on native valves reported in the literature dating back to 1912. We now report 11 cases of pneumococcal endocarditis in children seen since 1993 by the US Pediatric Multicenter Pneumococcal Surveillance Group.
PATIENTS AND METHODS
The US Pediatric Multicenter Pneumococcal Surveillance Group consists of investigators from 8 children's hospitals. Since 1993, these investigators have prospectively identified children seen at their centers with in-vasive disease due to S. pneumoniae (documented by isolation from a normally sterile body site) [6] . For the current study, further information was gathered retrospectively for each case of endocarditis identified during the period of 1 September 1993 through 28 February 2003.
The pneumococcal isolates from each center were sent to a central laboratory (Infectious Disease Research Laboratory, Texas Children's Hospital, Houston). Isolates were serogrouped or serotyped by the capsular swelling method with commercially available antisera (Statens Seruminstitut; Dako) [6] . Susceptibility testing for penicillin and ceftriaxone was performed by standard microbroth dilution with Mueller-Hinton media supplemented with 3% lysed horse blood. Susceptibility was defined according to the 2003 NCCLS guidelines for MICs for nonmeningitis or meningitis, as appropriate [7] . according to the modified Duke criteria [3, 8] . The patients ranged in age from 7 months to 14.5 years, with a median age of 15 months; 3 (27%) were aged !1 year, 7 (64%) were aged !2 years, and 7 (64%) were aged 3-36 months. Eight patients (73%) were boys. Only 1 child (9%) had no history of structural heart disease (and no other underlying condition). Among the 10 patients with structural heart disease, 5 had previous heart surgery (4 of whom had indwelling vascular grafts or patches). One child (patient 1) had undergone cardiac surgery in the previous 2 months, and 1 (patient 5) of the 2 children with mitral valve prolapse had dental work performed in the previous month without receiving antimicrobial prophylaxis. Two patients (both of whom had heart disease) had central vascular catheters in place at the time of diagnosis. Two patients had trisomy 21 as well as preexisting heart disease. The duration of symptoms ). WBC differential counts revealed immature neutrophils ranging 0%-62% (median, 13%). Five patients (45%) had у20% immature neutrophils. The platelet count was low in only 2 children (20,000 cells/mm 3 in one and 145,000 cells/ mm 3 in the other). A hemoglobin level of !10 g/dL (range, 9.1-9.8 g/dL) was noted in 4 (36%). The erythrocyte sedimentation rate (ESR) was measured in 9 patients; aside from patient 4, whose ESR was 5 mm/h (this child's hemoglobin level was 15.7 g/dL), the ESRs were in the range of 32-105 mm/h. The C-reactive protein level was measured in only 3 patients and was 1.6, 1.6, and 4.7 mg/dL in patients whose ESRs were 5 mm/h, not performed, and 105 mm/h, respectively. Rheumatoid factor was tested in only 1 patient, and the result was negative. Hematuria (i.e., 15 RBCs/high-power field) was noted in 2 (22%) of 9 patients tested.
All patients were evaluated by transthoracic echocardiography (table 1) ; none underwent a transesophageal study. Vegetations were detected in 7 patients (64%); in 6 patients, they were noted on the first echocardiogram obtained, and in the other patient, they were noted on the second. Possible vegetations were noted in 1 child (patient 2). No vegetations were detected in 3 patients.
Blood cultures were positive for S. pneumoniae in all patients; the number of positive culture results and the number of samples obtained before the initiation of appropriate antimicrobial therapy are shown in table 1. Only 2 patients (18%) had a single positive blood culture result before initiating therapy. Cardiac cultures positive for S. pneumoniae included (in one patient each) cultures of specimens of the tricuspid valve, pericardial fluid, and pericardial fluid and pulmonary artery aneurysm.
Other sites of infection included (table 1) meningitis (1 patient); pneumonia (1 patient); and meningitis and pneumonia (2 patients). Of the 3 patients with meningitis, 2 had CSF specimens that were culture positive for S. pneumoniae, whereas the third had CSF pleocytosis with a positive Gram stain result after receipt of 2 days of intravenous antimicrobials (patient 6; table 1). One patient each had sinusitis and acute otitis media.
Four patients had positive blood culture results during appropriate intravenous antibiotic therapy for endocarditis; in these patients, the last positive culture sample was obtained on days 1, 1, 2, and 9 of therapy. In the 10 patients with available information, the duration of intravenous antibiotic therapy preceding defervescence was 1-15 days (median, 3 days), with 7 patients being afebrile by day 3 of therapy.
Primary therapy for endocarditis consisted of cefotaxime or ceftriaxone for 5 patients, cefotaxime and vancomycin in 2, penicillin for 2, and clindamycin for 1, and 1 patient received many of the aforementioned antibiotics (table 1) . Excluding patient 8, who died on the 16th day of therapy, patients received intravenous antibiotics for 28-59 days (mean, 39 days). Patients remained hospitalized for 3-48 days (median, 8.5 days). Only 2 patients remained hospitalized for their entire course of parenteral therapy; the other 8 were discharged after 3-35 days, with 4 patients discharged after р5 days. Six patients experienced serious complications as a result of endocarditis, including significant valvular regurgitation, mitral valve leaflet perforation, aortic root abscess, mycotic aneurysm, stroke with hemiparesis and seizures, and atrioventricular block (table 1). Four of these patients required cardiac surgery during their hospitalization; patient 8 died during aortic valve replacement. Two other children died soon after discharge: patient 6 had undergone cardiac valve replacement while hospitalized for endocarditis and died 18 months later as a result of intracranial hemorrhage while receiving anticoagulant therapy; patient 9 died 5 months after hospitalization after experiencing an acute cardiopulmonary arrest while at home.
Microbiological studies. Antibiotic susceptibility testing was performed at the central laboratory for 10 isolates and at the local laboratory for 1 isolate. Of the 11 total isolates (table 1), 8 (73%) were susceptible, 2 (18%) had intermediate resistance, and 1 (9%) was resistant to penicillin, and all isolates were susceptible to ceftriaxone. The 3 isolates from patients with concomitant meningitis were susceptible to penicillin and ceftriaxone by NCCLS guidelines for meningitis. Ten patients' pneumococcal isolates were available for serogrouping and serotyping (table 1). Serotype 14 was the most common (4 patients), followed by serogroup 18 (2 patients).
DISCUSSION
Endocarditis occurs less commonly in children than in adults, although the incidence of endocarditis in children may be increasing as a result of many factors, including increased survival of children with congenital heart disease and increased use of central vascular catheters [4] . In our series, 10 (91%) of 11 children with pneumococcal endocarditis had underlying structural heart disease; 5 of these 10 had undergone previous heart surgery (4 of whom had indwelling vascular grafts or patches). These relative numbers are consistent with those previously reported in children with endocarditis [4] . The 5 children with heart disease without previous heart surgery had ventricular septal defect (3 patients, including a patient who also had atrial septal defect and duplicated superior vena cava) or mitral valve prolapse (2 patients). Other studies of pediatric endocarditis have noted that ventricular septal defect predominated among subjects with acyanotic congenital heart disease [2, 9] . Mitral valve prolapse had not been diagnosed previously in either of our 2 patients found to have it when they presented with endocarditis, a scenario reported in many children in a previous study of endocarditis [9] . Two children with underlying heart disease also had central vascular catheters in place.
The median age in our study was 15 months; the median ages in other recently published series of endocarditis in children were 8.2 years [9] and 9 years [2] . This difference likely relates, at least in part, to our series being limited to patients with pneumococcal endocarditis; 7 (64%) of our patients were 3-36 months of age and thus at higher risk for pneumococcal bacteremia [10] . During the 9.5-year study period in which we identified 11 cases of pneumococcal endocarditis, our study group identified a total of 3065 children with pneumococcal bacteremia (data not shown); thus, endocarditis occurred in 0.4% of them. Among adults, endocarditis has been noted to occur in 0.8%-4.3% of those with pneumococcal bacteremia [11] [12] [13] [14] .
Also of interest, 73% of our patients were boys. A male predominance has been noted in other recent studies of endocarditis in children [2, 9] , as well as in studies of pneumococcal endocarditis in adults [12] [13] [14] [15] [16] . In 1990, Bruyn et al. [11] found a statistically significant ( ) predominance of P p .01 male patients (27 men among 36 adults) for cases of pneumococcal endocarditis reported in the literature during the 5 years before their publication.
Our patients often presented with a variety of nonspecific complaints, as is usual in childhood endocarditis [4] . Compared with adults, children presenting with endocarditis are less likely to have classic peripheral vascular (e.g., petechiae) and immunologic (e.g., glomerulonephritis) phenomena [2, 4] ; this also appeared to be true in our series. This may be related to shorter duration of illness before diagnosis in children than in adults [2] . In our study, the median duration of symptoms before initiation of therapy was 4 days. In recently published studies of adults with pneumococcal endocarditis, the median duration of symptoms before therapy was 7 days in 1 study [13] and 16 days in each of 2 other studies [14, 16] . Even among adults, however, classic vascular and immunologic phenomena may be less likely with pneumococcal endocarditis than with other causes of infectious endocarditis; perhaps this is related to a more acute onset [15] . Fever was present in all of our patients. In recent studies of endocarditis in children, fever has been noted to be present in 96% of 108 episodes [3] and 99% of 76 episodes [2] .
Transthoracic echocardiography demonstrated definite vegetations in 7 (88%) of 8 patients without complex cyanotic heart disease (the eighth patient had a possible vegetation noted). This rate of positivity is similar to that noted previously in children with endocarditis [4] . Among the 3 children with complex cyanotic heart disease (patients 1, 4, and 9), no vegetations were detected. The lower rate of positivity in children with complex cyanotic heart disease also has been noted in previous studies [4, 9] .
Among our 11 patients, 1 had pneumonia, 1 had meningitis, and 2 had pneumonia and meningitis. In adults with pneumococcal endocarditis, pneumonia and meningitis are common concomitant manifestations of infection [12] [13] [14] [15] [16] ; these 3 manifestations of infection are together referred to as "Osler's triad" [16] . Three patients (27%) in our series (ranging in age from 14 months to 14 years) had concomitant pneumococcal meningitis, underscoring the need to evaluate patients with pneumococcal endocarditis carefully for the possibility of meningeal infection.
As expected, our patients received extended courses of parenteral therapy. Only 2 patients remained hospitalized for their entire course of therapy, with 4 patients discharged after р5 days.
Complications were common in this study (table 1) , with 4 patients (36%) requiring cardiac surgery during hospitalization. In other recent series of endocarditis in children, 15 (21%) of 73 [2] and 12 (22%) of 55 [9] required surgery. In our study, 1 patient died during hospitalization (9% mortality rate). Recent series of endocarditis in children have noted mortality rates of 11%-18% [2, 9] .
Few of our 11 patients had pneumococci that were nonsusceptible to penicillin, and all isolates were susceptible to ceftriaxone. Most treatment regimens included ceftriaxone or cefotaxime. We cannot comment on the effect of antibiotic resistance on presentation or outcome, nor can we comment on optimal therapy. Although limited data are available, in a study of 63 adults in Spain with pneumococcal endocarditis during the years of 1978-1998, penicillin resistance appeared to have no effect on clinical manifestations or complications [12] . Cases of endocarditis due to pneumococci resistant to both penicillin and ceftriaxone have been reported in adults and children; treatment with vancomycin alone or in combination with rifampin has been successful in such cases [17, 18] . Optimal therapy for pneumococcal endocarditis has not been established for adults or children [4, 19] .
Serotypes/serogroups 14 and 18 accounted for 60% of the pneumococcal isolates in our series. Aronin et al. [15] , in their 1998 review of the English-language literature on pneumococcal endocarditis in adults, note that the most commonly identified serotypes are 12, 1, and 8. In a review of adults with pneumococcal endocarditis seen in Denmark during the years of 1986-1997 [14] , serotype information was available for 12 patients; 2 patients each had 12F and 22F serotypes, 1 patient had serotype 14, and none had serotype 18. Similarly, among adults in the Alaska native population with pneumococcal endocarditis seen between 1978 and 1990, serotype data were available for 5 patients [13] : 2 had serotype 12F, and none had serotype 14 or 18. During the first 6 years (1993-1999) of surveillance by our US Pediatric Multicenter Pneumococcal Surveillance Group, overall, serotypes/serogroups 14 and 18 accounted for 27% and 7%, respectively, of the 2399 isolates from children with invasive pneumococcal disease [20] .
The 7-valent conjugated pneumococcal vaccine recommended for universal use in young children in the United States includes pneumococcal serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F [21] . Eight of the 10 isolates recovered from our patients with endocarditis (table 1) were vaccine or vaccine-related serotypes. This vaccine was licensed in 2000; thus, only our patient presenting in 2003 had received it (patient 11 received a single dose 3 weeks before onset of disease due to serotype 14). At least 1 of our patients (patient 8; isolate not serotyped) may have been a candidate for the 23-valent polysaccharide pneumococcal vaccine that has been licensed since 1983 and recommended since 1997 by the Advisory Committee on Immunization Practices for patients at least 2 years of age with chronic cardiovascular disease and other high-risk conditions [22] . The pneumococcal vaccines should be used as recommended [21] . Their ability to prevent pneumococcal endocarditis is unknown but likely; the conjugate vaccine recommended for universal use has been shown to be highly effective in the prevention of invasive pneumococcal disease in children [23] .
